Characterizing RAPIDTM platelet and leukocyte-rich plasma gels – an autologous, point-of-care medicine for diabetic foot ulcer treatment
In 2017/18 wound healing cost the NHS 8.3 billion pounds. There is an urgent need for more effective, accessible, and safe treatments. Platelet-rich plasma (PRP) therapies have been emerging since the early 2000s, currently they are used across various medical fields treating conditions from cosmeti...
Main Authors: | Aleksandra Olszewska, Simon Pitchford, James Rickard, Ben Forbes |
---|---|
Format: | Article |
Language: | English |
Published: |
University of Huddersfield Press
2022-11-01
|
Series: | British Journal of Pharmacy |
Subjects: | |
Online Access: | https://www.bjpharm.org.uk/article/id/1178/ |
Similar Items
-
The Potential of Autologous Platelet-Rich Plasma Gel for Diabetic Foot Ulcer Care Among Older Adults: A Systematic Review and Meta-Analysis
by: Platini H, et al.
Published: (2024-01-01) -
Platelet-rich plasma for the treatment of diabetic foot ulcer: a systematic review
by: Hong OuYang, et al.
Published: (2023-11-01) -
The role of VEGF, PDGF and IL-6 on diabetic foot ulcer after Platelet Rich Fibrin + hyaluronic therapy
by: Ronald W. Kartika, et al.
Published: (2021-09-01) -
Wound Healing in Diabetic Foot Ulcer Patients Using Combined Use of Platelet Rich Fibrin and Hyaluronic Acid, Platelet Rich Fibrin and Placebo: An Open Label, Randomized Controlled Trial
by: Ronald Winardi Kartika, et al.
Published: (2021-07-01) -
The role of allogeneic platelet-rich plasma in patients with diabetic foot ulcer: Current perspectives and future challenges
by: Min He, et al.
Published: (2022-09-01)